KRRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Korro Bio Inc (KRRO) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive analyst sentiment, significant hedge fund buying activity, and promising developments in its lead program KRRO-121 addressing unmet medical needs. Despite weak financials in the last quarter, the long-term growth potential outweighs the short-term challenges.
The MACD is positive and contracting, RSI is neutral at 49.869, and moving averages are converging, indicating no strong trend. The stock is trading near its pivot level of 13.588, with resistance at 14.369 and support at 12.807. Technical indicators suggest a stable price trend with potential for upward movement.
Analysts have significantly upgraded the stock with price targets as high as $30, citing strong preclinical data and a promising regulatory path for KRRO-
Hedge funds have increased their buying activity by 1445.31% over the last quarter.
The stock's probability of success has been reset with a fresh focus on addressing hyperammonemia, a high unmet medical need.
Financial performance in Q4 2025 showed a revenue drop of -43.11% YoY and a net income loss of -$50.04M.
No recent news or congress trading data to provide additional sentiment or validation.
In Q4 2025, revenue dropped by -43.11% YoY to $1.29M, while net income improved to -$50.04M, up 136.06% YoY. EPS also improved to -5.32, up 135.40% YoY. Despite revenue decline, the company shows progress in reducing losses.
Analysts are overwhelmingly positive, with multiple upgrades to Buy or Outperform and price targets ranging from $15 to $30. Analysts highlight strong preclinical data for KRRO-121 and its potential to address unmet medical needs in hyperammonemia and hepatic encephalopathy.
